Lantheus Medical Imaging Purchases Balance of Worldwide Rights for MRA Imaging Agent ABLAVAR(R) (Gadofosveset Trisodium)
N. BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that it has acquired the balance of the worldwide rights for gadofosveset trisodium, a unique, injectable magnetic resonance angiography (MRA) blood pool imaging agent that it currently markets in the United States as ABLAVAR®. ABLAVAR® is indicated for use in adults with known or suspected peripheral vascular disease to evaluate aortoiliac occlusive disease. Lantheus purchased the worldwide rights in a recent auction of the remaining assets of EPIX Pharmaceuticals. The company already owns exclusive rights to ABLAVAR® in the United States, Canada and Australia. Terms of the purchase were not announced.